Zealand Pharma's stock fell 22% after a late-stage trial of Boehringer Ingelheim’s weight-loss drug survodutide revealed about 20% of users stopped treatment due to gastrointestinal side effects, compared to under 3% on placebo. This low tolerability could limit the drug's use in the obesity market, according to Goldman Sachs analysts. The results raise concerns about the drug's commercial potential despite its efficacy. Investors reacted negatively, reflecting uncertainty about the drug's future adoption.
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
Several stocks experienced significant declines today driven by company-specific events. SANUWAVE Health's shares dropped 39.21% despite strong revenue guidance, Twin Vee Powercats fell 30.95% amid a legal investigation, and Gorilla Technology declin...
The stock market saw significant gains driven by corporate announcements and high trading volumes, particularly in battery technology, electric vehicles, and green energy sectors. Electrovaya surged 49.05% after announcing a commercial deal with Amaz...
An Akamai Technologies executive sold 3,100 shares as the company shifts focus from its declining content delivery network business to high-growth cloud infrastructure and cybersecurity services. This strategic pivot is supported by a $1.8 billion, s...
Taiwan Semiconductor Manufacturing Company (TSMC) is set to report earnings on July 16, 2026, with analysts expecting revenue around $39.85 billion, up significantly from last year due to high demand for AI chips. Earnings per share are forecasted at...
